EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1

Yves Dauvilliers, Giuseppe Plazzi, Emmanuel Mignot, Gert Jan Lammers, Rafael Del Río Villegas iD, Ramin Khatami, Mitsutaka Taniguchi, Anson Abraham, Yaming Hang, Harisha Kadali, Marta Lamberton, Sarah Sheikh und 10 weitere

New England Journal of Medicine · 15.05.2025 · 392 (19) · 1905-1916

DOI: 10.1056/nejmoa2405847 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 15.05.2025. Verfasst von Yves Dauvilliers und 21 weiteren Autor:innen. Beteiligte Einrichtung: National Reference Network for Narcolepsy, Sleep and Wake Disorders Center, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France. Hauptthemen laut MEDLINE: Cataplexy, Narcolepsy, Orexin Receptors, Sleep Initiation and Maintenance Disorders. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Takeda Development Center Americas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CataplexyNarcolepsyOrexin ReceptorsSleep Initiation and Maintenance DisordersAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralDouble-Blind MethodSleep LatencyWakefulnessIncidenceUrinationTreatment Outcome

Substanzen

Orexin Receptors

Autor:innen und Institutionen

  • National Reference Network for Narcolepsy, Sleep and Wake Disorders Center, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France.
  • University of Montpellier, INSERM Institute for Neurosciences Montpellier, Montpellier, France.
  • IRCCS, Istituto delle Scienze Neurologiche, Bologna, Italy.
  • Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Stanford Center for Sleep Sciences and Medicine, Redwood City, CA.
  • Sleep-Wake Center, Stichting Epilepsie Instellingen Nederland, Heemstede, the Netherlands.

ORCID-Profile: Rafael Del Río Villegas

Förderung

  • Takeda Development Center Americas

Zitieren

APA

Dauvilliers, Y., Plazzi, G., Mignot, E., Lammers, G. J., Del Río Villegas, R., Khatami, R., Taniguchi, M., Abraham, A., Hang, Y., Kadali, H., Lamberton, M., Sheikh, S., Stukalin, E., Neuwirth, R., Swick, T. J., Tanaka, S., von Hehn, C., von Rosenstiel, P., Wang, H., …, & Olsson, T. (2025). Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1. New England Journal of Medicine, 392(19), 1905-1916. https://doi.org/10.1056/nejmoa2405847

Vancouver

Dauvilliers Y, Plazzi G, Mignot E, Lammers GJ, Del Río Villegas R, Khatami R, et al. Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1. New England Journal of Medicine. 2025;392(19):1905-1916. doi:10.1056/nejmoa2405847

BibTeX
@article{Dauvilliers2025,
  author = {Dauvilliers, Yves and Plazzi, Giuseppe and Mignot, Emmanuel and Lammers, Gert Jan and Del Río Villegas, Rafael and Khatami, Ramin and Taniguchi, Mitsutaka and Abraham, Anson and Hang, Yaming and Kadali, Harisha and Lamberton, Marta and Sheikh, Sarah and Stukalin, Ellie and Neuwirth, Rachel and Swick, Todd J and Tanaka, Shinichiro and von Hehn, Christian and von Rosenstiel, Philipp and Wang, Hao and Cai, Alice and Naylor, Melissa and Olsson, Tina},
  title = {Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {19},
  pages = {1905--1916},
  doi = {10.1056/nejmoa2405847}
}
Kostenlos starten →